Acid-suppressive effects of rabeprazole: Comparing 10mg and 20mg twice daily in Japanese Helicobacter pylori-negative and -positive CYP2C19 extensive metabolisers
- 30 November 2006
- journal article
- research article
- Published by Elsevier in Digestive and Liver Disease
- Vol. 38 (11), 802-808
- https://doi.org/10.1016/j.dld.2006.06.002
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: A crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19Clinical Pharmacology & Therapeutics, 2006
- Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease: A randomised, double-blind, comparative study of rabeprazole and omeprazole 20mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazoleDigestive and Liver Disease, 2005
- Acid-Suppressive Efficacy of a Reduced Dosage of Rabeprazole: Comparison of 10 Mg Twice Daily Rabeprazole with 20 Mg Twice Daily Rabeprazole, 30 Mg Twice Daily Lansoprazole, and 20 Mg Twice Daily Omeprazole by 24-Hr Intragastric pH-metryDigestive Diseases and Sciences, 2005
- Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary studyDigestive and Liver Disease, 2003
- Current concepts in the management of Helicobacter pylori infection—The Maastricht 2‐2000 Consensus ReportAlimentary Pharmacology & Therapeutics, 2002
- Rabeprazole produces rapid, potent, and long‐acting inhibition of gastric acid secretion in subjects with Helicobacter pylori infectionAlimentary Pharmacology & Therapeutics, 2000
- A placebo-controlled study to assess the effects of 7-day dosing with 10, 20 and 40 mg rabeprazole on 24-h intragastric acidity and plasma gastrin in healthy male subjectsAlimentary Pharmacology & Therapeutics, 2000
- Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infectionJournal of Gastroenterology and Hepatology, 1998
- The proton pump inhibitor, E3810, binds to the N-terminal half of the α-subunit of gastric H+,K+-ATPaseBiochemical Pharmacology, 1995
- Inhibitions of acid secretion by E3810 and omeprazole, and their reversal by glutathioneBiochemical Pharmacology, 1991